New vaccine trial targets deadly diarrhea bug
NCT ID NCT07205926
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new vaccine called IVT Shigella-04 to see if it is safe and helps the immune system fight Shigella bacteria, a major cause of severe diarrhea. About 60 healthy adults aged 18 to 49 will receive two shots of either the vaccine or a placebo. Researchers will monitor side effects and measure immune responses over six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medpace Clinical Pharmacology Unit
RECRUITINGCincinnati, Ohio, 45227, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••